578 related articles for article (PubMed ID: 33205034)
21. Immune Checkpoint Inhibitors-Induced Hepatitis.
Tian Y; Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2018; 995():159-164. PubMed ID: 30539511
[TBL] [Abstract][Full Text] [Related]
22. Review of immune checkpoint inhibitors in immuno-oncology.
Jacob JB; Jacob MK; Parajuli P
Adv Pharmacol; 2021; 91():111-139. PubMed ID: 34099106
[TBL] [Abstract][Full Text] [Related]
23. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer.
Iranzo P; Callejo A; Assaf JD; Molina G; Lopez DE; Garcia-Illescas D; Pardo N; Navarro A; Martinez-Marti A; Cedres S; Carbonell C; Frigola J; Amat R; Felip E
Front Med (Lausanne); 2022; 9():875974. PubMed ID: 35707528
[TBL] [Abstract][Full Text] [Related]
24. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor.
Sawada K; Hayashi H; Nakajima S; Hasebe T; Fujiya M; Okumura T
J Gastroenterol Hepatol; 2020 Jun; 35(6):1042-1048. PubMed ID: 31752049
[TBL] [Abstract][Full Text] [Related]
25. The ABC of Immune-Mediated Hepatitis during Immunotherapy in Patients with Cancer: From Pathogenesis to Multidisciplinary Management.
Lasagna A; Sacchi P
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398187
[TBL] [Abstract][Full Text] [Related]
26. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
[TBL] [Abstract][Full Text] [Related]
27. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.
El Osta B; Hu F; Sadek R; Chintalapally R; Tang SC
Crit Rev Oncol Hematol; 2017 Nov; 119():1-12. PubMed ID: 29065979
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis.
Gemelli M; Cortinovis DL; Baggi A; di Mauro P; Calza S; Berruti A; Grisanti S; Rota M
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551550
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
30. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
[TBL] [Abstract][Full Text] [Related]
31. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
32. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
33. Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.
Choi J; Lee SY
Immune Netw; 2020 Feb; 20(1):e9. PubMed ID: 32158597
[TBL] [Abstract][Full Text] [Related]
34. Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review.
Gao L; Yang X; Yi C; Zhu H
Front Pharmacol; 2019; 10():1173. PubMed ID: 31680957
[No Abstract] [Full Text] [Related]
35. Autoimmune complications of immunotherapy: pathophysiology and management.
Chan KK; Bass AR
BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223
[TBL] [Abstract][Full Text] [Related]
36. Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors.
Chen KY; Popovic A; Hsiehchen D; Baretti M; Griffith P; Bista R; Baghdadi A; Kamel IR; Simon SM; Migler RD; Yarchoan M
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358766
[TBL] [Abstract][Full Text] [Related]
37. Knowledge of Herbal Medicines - Is a Reverse Bridge Course an Urgent Necessity?
Parikh P
J Clin Exp Hepatol; 2022; 12(1):249-251. PubMed ID: 35035159
[No Abstract] [Full Text] [Related]
38. Immune checkpoint inhibitor-related hepatotoxicity: A review.
Remash D; Prince DS; McKenzie C; Strasser SI; Kao S; Liu K
World J Gastroenterol; 2021 Aug; 27(32):5376-5391. PubMed ID: 34539139
[TBL] [Abstract][Full Text] [Related]
39. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
40. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]